文献速递淋巴瘤

结外鼻型NK/T细胞淋巴瘤列线图修订风险指数在现代化疗时代的验证与模型比较

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.
PubMed 文献 · Leukemia · 2020-03-09

基于1383例以蒽环类化疗为主的结外鼻型NK/T细胞淋巴瘤(ENKTCL)患者多因素分析变量,提出列线图修订风险指数(NRI);在1582例以非蒽环类化疗为主的患者中验证,NRI对3年和5年总生存(OS)的校准满意,Harrell C指数与IBS优于Ann Arbor分期、IPI、KPI和PINK,决策曲线分析亦更优。

要点

  • NRI在验证队列中对3年和5年OS校准满意。
  • NRI的Harrell C指数和IBS优于Ann Arbor分期、IPI、KPI和PINK。
  • NRI决策曲线分析结果更优,可用于风险分层与个体化治疗选择。

核心结论

  • NRI是有前景的工具,可将ENKTCL患者分层为不同风险组,用于设计临床试验和选择适当的个体化治疗。

研究设计与样本

  • 从1383例ENKTCL患者(多数接受蒽环类化疗)的多因素分析风险变量中提出易用的列线图修订风险指数(NRI)。
  • 在1582例主要接受非蒽环类化疗的患者验证队列中,通过校准、区分度和决策曲线分析验证NRI,并与Ann Arbor分期、IPI、KPI和PINK比较OS预测。
  • 来源类型为PubMed收录的Leukemia研究。

主要发现

  • NRI在验证队列中对3年和5年OS预测的校准满意。
  • NRI预测OS的Harrell C指数和IBS表现优于Ann Arbor分期系统、IPI、KPI和PINK。
  • NRI的决策曲线分析也显示更优结果。

临床怎么用

  • 可用NRI对ENKTCL患者进行风险分层,辅助临床试验设计与个体化治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell's C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chen SY, Yang Y, Qi SN, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2020. PMID: 32152465. doi:10.1038/s41375-020-0791-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。